SCHEMBL392490

SCHEMBL392490

CC(=O)OC(C)OC(=O)Cl

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
TBXA2R P21731 1/20 0.38
GALR3 O60755 1/20 0.37
MAPT P10636 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 2/20 0.32
TRPV1 Q8NER1 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PGR P06401 1/20 0.31
PTGS1 P23219 1/20 0.31
PDE4A P27815 1/20 0.31
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22299925 0.89 TSHR (0.38) TSHRALDH1A1
SCHEMBL987906 0.86 TSHR (0.65) TSHRCHRM2CHRM4CHRM1TBXA2R
Acetic Acid SCHEMBL11076307 0.80 TSHR (0.58) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL2262906 0.78 TSHR (0.35) TSHR
SCHEMBL3814630 0.78 TSHR (0.55) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL9747539 0.78 TSHR (0.59) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL8606023 0.77 COMT (0.31) TSHR
SCHEMBL11043313 0.77 TSHR (0.42) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL8574824 0.77 TSHR (0.42) TSHRALDH1A1
SCHEMBL10403865 0.76 TSHR (0.52) TSHRCHRM2CHRM4CHRM1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 US disclosed
EP-4282867-A1 INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2023-11-29 EP disclosed
CN-105801489-B Cycloalkyl-substituted imidazole derivatives 第一三共株式会社 2019-12-10 CN disclosed
EP-2548871-B1 CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2017-07-19 EP disclosed
EP-2548871-B1 CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2017-07-19 EP disclosed
US-9340531-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-17 US disclosed
US-9340531-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-17 US disclosed
US-9340531-B2 Cycloalkyl-substituted imidazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-05-17 US disclosed
WO-2015006535-A2 DICTYOSTATIN PRODRUGS AND METHODS OF THEIR USE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-01-15 WO disclosed
US-20140178349-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-06-26 US disclosed
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-24 US disclosed
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-24 US disclosed
EP-2548871-A1 CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-23 EP disclosed
EP-2548871-A1 CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-23 EP disclosed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed
US-5789595-A ANTICOAGULANTS TERUMO KABUSHIKI KAISHA (JP) 1998-08-04 US disclosed
EP-0790247-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND MEDICINAL PREPARATION CONTAINING THE SAME TERUMO KABUSHIKI KAISHA (JP) 1997-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022587-A1 Cycloalkyl-Substituted Imidazole Derivative F7, F12, TFPI TSHR 13/4885CHRM2 56/4885CHRM4 105/4885
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF GHSR, GHRHR, NR3C2 TSHR 44/4885CHRM2 2889/4885CHRM4 3240/4885
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 TSHR 2245/4885CHRM2 1784/4885CHRM4 2893/4885
US-20140178349-A1 Cycloalkyl-Substituted Imidazole Derivative F7, F12, TFPI TSHR 13/4885CHRM2 56/4885CHRM4 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.